Entropy Neurodynamics Limited (ASX:ENP)

Market Cap	49.95M
Revenue (ttm)	1.58M +19.2%
Net Income	-5.33M
EPS	-0.00
Shares Out	1.61B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,230,185
Average Volume	2,681,262
Open	0.0300
Previous Close	0.0310
Day's Range	0.0300 - 0.0320
52-Week Range	0.0270 - 0.0460
Beta	n/a
RSI	46.76
Earnings Date	n/a

About Entropy Neurodynamics

Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company’s lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. It is also ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ENP

Financial Performance

In 2025, Entropy Neurodynamics's revenue was 1.58 million, an increase of 19.17% compared to the previous year's 1.33 million. Losses were -5.33 million, -27.66% less than in 2024.